Andrea Mayer-Mokler

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

Steffen Walter, Toni Weinschenk, Arnulf Stenzl et al. · Nature Medicine · 2012 · 784 citations

Medicine, Immunology, Oncology +17

Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial

Martin Wermke, Dejka M Araurjo, Manik Chatterjee et al. · Nature Medicine · 2025 · 46 citations · Full text

Life Sciences, Immunology, Oncology +17

First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumors

Martin Wermke, Tobias A.W. Holderried, Jason J. Luke et al. · Journal for ImmunoTherapy of Cancer · 2024 · 27 citations · Full text

Medicine, Immunology, Oncology +17

959 Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine® IMA203 trial

Martin Wermke, Apostolia M. Tsimberidou, Ali Mohamed et al. · 2021 · 17 citations · Full text

Medicine, Immunology, Oncology +17

A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas

Atsuro Saijo, Hirokazu Ogino, Nicholas Butowski et al. · Neuro-Oncology · 2023 · 17 citations · Full text

Medicine, Immunology, Oncology +17